EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long‐term disease control of disseminated superficial actinic porokeratosis (DSAP) with simvastatin 2%/ cholesterol 2% cream

Berenice M Lang iD, Gregor Ojak iD, Mandy Crummenauer, Joanna Wegner, Caroline Mann iD, Stephan Grabbe, Petra Staubach

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2026

DOI: 10.1111/ddg.15950 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2026. Verfasst von Berenice M Lang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University medicine Mainz, Mainz, Germany. Hauptthemen laut MEDLINE: Cholesterol, Porokeratosis, Simvastatin, Skin Cream. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Disseminated superficial actinic porokeratosis (DSAP) is a rare keratinization disorder associated with an increased risk of cutaneous tumors.

Objectives

To develop a feasible and easy‐to‐apply treatment regimen for long‐time disease control of DSAP including prevention of new skin tumors. Patients and Methods 19 patients with DSAP were treated with 2% simvastatin/2% cholesterol (SC) cream for a maximum period of 18 months. Disease severity was assessed via Investigator Global Assessment (IGA), and quality of life (QoL) was measured using the Dermatology Life Quality Index (DLQI). Adverse events and tumor development were documented.

Results

Significant improvement in IGA scores was observed across all treated regions (p < 0.001), with most progress occurring in the first 3 months but maintained under a reduced proactive application schedule twice weekly. DLQI scores decreased significantly within the first 3 months. No new skin tumors developed during treatment.

Conclusions

SC cream is a promising long‐term, targeted treatment for DSAP, offering sustained efficacy, good tolerability, and improved QoL. The individual tapering from daily use to a proactive approach twice a week may be a key factor for disease control and may become an important component of skin tumor prevention in this specific patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholesterolPorokeratosisSimvastatinSkin CreamAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdministration, CutaneousQuality of LifeSkin NeoplasmsTreatment Outcome

Stichwörter der Autor:innen

Disease controlporokeratosisskin cancer preventiontargeted therapytopical therapyunmet medical need

Substanzen

CholesterolSimvastatin

Autor:innen und Institutionen

  • Department of Dermatology, University medicine Mainz, Mainz, Germany.
  • Department of Dermatology, University medicine Frankfurt, Frankfurt am Main, Germany.
  • Dermatology Center, Kaiserslautern, Germany.

ORCID-Profile: Berenice M Lang, Gregor Ojak, Caroline Mann

Zitieren

APA

Lang, B. M., Ojak, G., Crummenauer, M., Wegner, J., Mann, C., Grabbe, S., & Staubach, P. (2026). Long‐term disease control of disseminated superficial actinic porokeratosis (DSAP) with simvastatin 2%/ cholesterol 2% cream. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15950

Vancouver

Lang BM, Ojak G, Crummenauer M, Wegner J, Mann C, Grabbe S, et al. Long‐term disease control of disseminated superficial actinic porokeratosis (DSAP) with simvastatin 2%/ cholesterol 2% cream. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.15950

BibTeX
@article{Lang2026,
  author = {Lang, Berenice M and Ojak, Gregor and Crummenauer, Mandy and Wegner, Joanna and Mann, Caroline and Grabbe, Stephan and Staubach, Petra},
  title = {Long‐term disease control of disseminated superficial actinic porokeratosis (DSAP) with simvastatin 2%/ cholesterol 2% cream},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2026},
  doi = {10.1111/ddg.15950}
}
Kostenlos starten →